Octinoxate

Identification

Name
Octinoxate
Accession Number
DB09496
Type
Small Molecule
Groups
Approved, Investigational
Description

Octinoxate is a cinnamate ester and common ingredient in sunscreen and other skin care products to minimize DNA photodamage. It was originally developed in 1950's as an organic UV-B filter that absorbs UV-B rays from sun. It is often combined with nanoparticles or other water-resistant liposomes in formulations to increase the localization at the epidermis and decrease the risk of percutaneous absorption. Its use in pharmaceutical and cosmetic formulations is approved by FDA.

Structure
Thumb
Synonyms
  • ethylhexyl methoxycinnamate
  • ethylhexyl p-methoxycinnamate
  • octyl methoxycinnamate
  • parsol
External IDs
Eusolex 2292 / Uvinul MC80
Active Moieties
NameKindUNIICASInChI Key
2-Ethylhexyl 4-phenylbenzophenone-2'-carboxylateunknown93NOD9WBCS75005-95-7TWAOKHHZKFMFMD-UHFFFAOYSA-N
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
125 Fl Moisture Whip Lipstick-stk Top 50mg/gStick50 mgTopicalMaybelline Canada1996-12-311998-07-11Canada
25 Creme 410Cream7.5 %TopicalMultaler & Cie2004-06-012008-03-28Canada
275lw Long Wearing Lipstick 50mg/gStick50 mgTopicalMaybelline Canada1996-12-311998-07-11Canada
4-IN-1 Liquid 14-hour Wear Foundation SPF 15Emulsion5 %TopicalPurminerals2013-02-202017-03-28Canada
6 Creme 410Cream5 %TopicalMultaler & Cie2004-12-012008-06-25Canada
6 Creme 410 TeinteeCream5 %TopicalMultaler & Cie2004-12-032013-07-31Canada
6 Creme 410 TeinteeCream5 g/100gTopicalMULTALER & CIE S.A.S2011-02-152017-05-11Us
6 Lait SolaireLotion5 %TopicalMultaler & Cie2004-12-012013-07-31Canada
675rl Revitalizing Lip Indulgence - Stk 7.5%Stick7.5 %TopicalMaybelline Canada1996-12-311999-07-30Canada
Absolue MakeupCream7.5 %TopicalLancome Canada2005-01-152014-02-10Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
01 Balancing Foundation SPF 15Octinoxate (3.75 mg/0.5mL) + Octisalate (2.5 mg/0.5mL) + Titanium dioxide (1.45 mg/0.5mL)EmulsionTopicalThe Body Shop, Wake Forest2009-09-062017-10-05Us
01 Moisture Foundation SPF 15Octinoxate (3.75 mg/0.5mL) + Zinc oxide (3.9 mg/0.5mL)EmulsionTopicalThe Body Shop, Wake Forest2009-09-06Not applicableUs
02 Balancing Foundation SPF 15Octinoxate (3.75 mg/0.5mL) + Octisalate (2.5 mg/0.5mL) + Titanium dioxide (1.45 mg/0.5mL)EmulsionTopicalThe Body Shop, Wake Forest2009-09-062017-10-05Us
02 Moisture Foundation SPF 15Octinoxate (3.75 mg/0.5mL) + Zinc oxide (3.9 mg/0.5mL)EmulsionTopicalThe Body Shop, Wake Forest2009-09-06Not applicableUs
03 Balancing Foundation SPF 15Octinoxate (3.75 mg/0.5mL) + Octisalate (2.5 mg/0.5mL) + Titanium dioxide (1.45 mg/0.5mL)EmulsionTopicalThe Body Shop, Wake Forest2009-09-062017-10-05Us
03 Moisture Foundation SPF 15Octinoxate (3.75 mg/0.5mL) + Zinc oxide (3.9 mg/0.5mL)EmulsionTopicalThe Body Shop, Wake Forest2009-09-06Not applicableUs
04 Balancing Foundation SPF 15Octinoxate (3.75 mg/0.5mL) + Octisalate (2.5 mg/0.5mL) + Titanium dioxide (1.45 mg/0.5mL)EmulsionTopicalThe Body Shop, Wake Forest2009-09-062017-10-05Us
04 Moisture Foundation SPF 15Octinoxate (3.75 mg/0.5mL) + Zinc oxide (3.9 mg/0.5mL)EmulsionTopicalThe Body Shop, Wake Forest2009-09-06Not applicableUs
05 Balancing Foundation SPF 15Octinoxate (3.75 mg/0.5mL) + Octisalate (2.5 mg/0.5mL) + Titanium dioxide (1.45 mg/0.5mL)EmulsionTopicalThe Body Shop, Wake Forest2009-09-062017-10-05Us
05 Moisture Foundation SPF 15Octinoxate (3.75 mg/0.5mL) + Zinc oxide (3.9 mg/0.5mL)EmulsionTopicalThe Body Shop, Wake Forest2009-09-06Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Alphaquin HPOctinoxate (75 mg/1g) + Hydroquinone (40 mg/1g) + Oxybenzone (50 mg/1g)CreamTopicalStratus Pharmaceuticals1993-01-012017-02-01Us
Condition and Enhance System Full-size Non-surgicalOctinoxate (75 mg/1mL) + Hydroquinone (40 mg/1g) + Hydroquinone (40 mg/1g) + Zinc oxide (90 mg/1mL)KitOMP, INC.2007-08-20Not applicableUs
Condition and Enhance System Travel-size Non-surgicalOctinoxate (75 mg/1mL) + Hydroquinone (40 mg/1g) + Hydroquinone (40 mg/1g) + Zinc oxide (90 mg/1mL)KitOMP, INC.2007-08-20Not applicableUs
Condition and Enhance System Travel-size SurgicalOctinoxate (75 mg/1mL) + Hydroquinone (40 mg/1g) + Hydroquinone (40 mg/1g) + Zinc oxide (90 mg/1mL) + Zinc oxide (185 mg/1g)KitOMP, INC.2007-08-20Not applicableUs
Glytone Clarifying SunVanish with SunscreenOctinoxate (75 mg/1g) + Avobenzone (20 mg/1g) + Hydroquinone (40 mg/1g) + Octocrylene (18.6 mg/1g) + Oxybenzone (50 mg/1g)CreamTopicalGenesis2012-06-13Not applicableUs
Glytone SunVanish Skin LighteningOctinoxate (75 mg/1g) + Avobenzone (20 mg/1g) + Hydroquinone (40 mg/1g) + Octocrylene (18.6 mg/1g) + Oxybenzone (50 mg/1g)CreamTopicalGenesis2012-06-13Not applicableUs
Merle Norman Preventage Hand Treatment SPF 15Octinoxate (2.147 g/113g) + Titanium dioxide (10.622 g/113g)CreamTopicalMerle Norman Cosmetics2012-09-012013-05-06Us
Nu-derm Starter Set Normal-dry Skin Transformation SystemOctinoxate (75 mg/1mL) + Octinoxate (75 mg/1g) + Hydroquinone (40 mg/1g) + Hydroquinone (40 mg/1g) + Hydroquinone (40 mg/1g) + Oxybenzone (55 mg/1g) + Zinc oxide (90 mg/1mL)KitOMP, INC.2007-08-20Not applicableUs
Nu-derm Starter Set Normal-dry Skin Transformation SystemOctinoxate (75 mg/1mL) + Octinoxate (75 mg/1g) + Hydroquinone (40 mg/1g) + Hydroquinone (40 mg/1g) + Hydroquinone (40 mg/1g) + Oxybenzone (55 mg/1g) + Zinc oxide (90 mg/1mL)KitOMP, INC.2007-08-20Not applicableUs
Nu-derm Starter Set Normal-oily Skin Transformation SystemOctinoxate (75 mg/1mL) + Octinoxate (75 mg/1g) + Hydroquinone (40 mg/1g) + Hydroquinone (40 mg/1g) + Hydroquinone (40 mg/1g) + Oxybenzone (55 mg/1g) + Zinc oxide (90 mg/1mL)KitOMP, INC.2004-12-02Not applicableUs
Categories
UNII
4Y5P7MUD51
CAS number
5466-77-3
Weight
Average: 290.3972
Monoisotopic: 290.188194698
Chemical Formula
C18H26O3
InChI Key
YBGZDTIWKVFICR-JLHYYAGUSA-N
InChI
InChI=1S/C18H26O3/c1-4-6-7-15(5-2)14-21-18(19)13-10-16-8-11-17(20-3)12-9-16/h8-13,15H,4-7,14H2,1-3H3/b13-10+
IUPAC Name
2-ethylhexyl (2E)-3-(4-methoxyphenyl)prop-2-enoate
SMILES
[H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC

Pharmacology

Indication

As an active ingredient in sunscreens and lip balms. Used for protection against damaging effects of sun rays.

Associated Conditions
Pharmacodynamics

Acts as a photoprotective agent that protects the skin by preventing and minimizing the damaging effects of ultraviolet (UV) rays of natural light. The cellular effects of UV irradiation include DNA damage, cell cycle arrest, immunological depression, apoptosis, and transcriptional changes [7].

Mechanism of action

Absorbs UV-B (predominantly) and UV-A rays while accumulating in the outermost layer of the epidermis. Like any other photoprotective agents, octinoxate prevents the damage to cells and deoxyribonucleic acid (DNA) by reducing the p53 protein expression following UV exposure [7] and also increases the skin's tolerability to UV rays [6].

Absorption

Can be systemically absorbed after skin application, being found in the deeper layers of the stratum corneum as well as urine, plasma, and breast milk [2]. The mean maximum plasma concentration detected after application of 2mg/cm2 sunscreen was 7ng/mL in women and 16ng/mL in men [6].

Volume of distribution
Not Available
Protein binding

None

Metabolism

Can undergo hepatic metabolism when systematically absorbed. Can be enzymatically degraded by lipases in the stratum corneum where esters undergo hydrolysis [2]. Degrade into photoproducts when exposed to sunlight, which leads to a decrease in UV absorption efficiency [6].

Route of elimination

Can be detected in urine in unchanged form [4].

Half life
Not Available
Clearance
Not Available
Toxicity

Slightly hazardous in case of skin contact, eye contact, ingestion and inhalation. Octinoxate may form reactive singlet oxygen species and induce anti-estrogenic effects [8]. UV-induced molecular breakdown of octinoxate may interfere with cellular processes or induce oxidative damage in human skin [6]. The NOAEL (no observed adverse effect level) is 450 mg/kg bw/day for fertility and reproductive performance, for systemic parental and developmental toxicity in Wistar rats [3].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Octinoxate which could result in a higher serum level.
AcarboseAcarbose may decrease the excretion rate of Octinoxate which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Octinoxate which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Octinoxate which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Octinoxate which could result in a higher serum level.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Octinoxate which could result in a higher serum level.
AclidiniumAclidinium may decrease the excretion rate of Octinoxate which could result in a higher serum level.
AcrivastineAcrivastine may decrease the excretion rate of Octinoxate which could result in a higher serum level.
AcyclovirAcyclovir may decrease the excretion rate of Octinoxate which could result in a higher serum level.
AdefovirAdefovir may decrease the excretion rate of Octinoxate which could result in a higher serum level.
Food Interactions
Not Available

References

General References
  1. Monteiro MS, Ozzetti RA, Vergnanini AL, de Brito-Gitirana L, Volpato NM, de Freitas ZM, Ricci-Junior E, dos Santos EP: Evaluation of octyl p-methoxycinnamate included in liposomes and cyclodextrins in anti-solar preparations: preparations, characterizations and in vitro penetration studies. Int J Nanomedicine. 2012;7:3045-58. doi: 10.2147/IJN.S28550. Epub 2012 Jun 20. [PubMed:22787399]
  2. Mota Ade C, de Freitas ZM, Ricci Junior E, Dellamora-Ortiz GM, Santos-Oliveira R, Ozzetti RA, Vergnanini AL, Ribeiro VL, Silva RS, dos Santos EP: In vivo and in vitro evaluation of octyl methoxycinnamate liposomes. Int J Nanomedicine. 2013;8:4689-701. doi: 10.2147/IJN.S51383. Epub 2013 Dec 10. [PubMed:24376350]
  3. Schneider S, Deckardt K, Hellwig J, Kuttler K, Mellert W, Schulte S, van Ravenzwaay B: Octyl methoxycinnamate: two generation reproduction toxicity in Wistar rats by dietary administration. Food Chem Toxicol. 2005 Jul;43(7):1083-92. [PubMed:15833384]
  4. Janjua NR, Mogensen B, Andersson AM, Petersen JH, Henriksen M, Skakkebaek NE, Wulf HC: Systemic absorption of the sunscreens benzophenone-3, octyl-methoxycinnamate, and 3-(4-methyl-benzylidene) camphor after whole-body topical application and reproductive hormone levels in humans. J Invest Dermatol. 2004 Jul;123(1):57-61. [PubMed:15191542]
  5. Hayden CG, Cross SE, Anderson C, Saunders NA, Roberts MS: Sunscreen penetration of human skin and related keratinocyte toxicity after topical application. Skin Pharmacol Physiol. 2005 Jul-Aug;18(4):170-4. Epub 2005 May 20. [PubMed:15908756]
  6. Latha MS, Martis J, Shobha V, Sham Shinde R, Bangera S, Krishnankutty B, Bellary S, Varughese S, Rao P, Naveen Kumar BR: Sunscreening agents: a review. J Clin Aesthet Dermatol. 2013 Jan;6(1):16-26. [PubMed:23320122]
  7. Duale N, Olsen AK, Christensen T, Butt ST, Brunborg G: Octyl methoxycinnamate modulates gene expression and prevents cyclobutane pyrimidine dimer formation but not oxidative DNA damage in UV-exposed human cell lines. Toxicol Sci. 2010 Apr;114(2):272-84. doi: 10.1093/toxsci/kfq005. Epub 2010 Jan 13. [PubMed:20071424]
  8. Maipas S, Nicolopoulou-Stamati P: Sun lotion chemicals as endocrine disruptors. Hormones (Athens). 2015 Jan-Mar;14(1):32-46. [PubMed:25885102]
  9. The Dermatology Review: Octinoxate [Link]
External Links
Human Metabolome Database
HMDB0061861
KEGG Drug
D05225
PubChem Compound
5355130
PubChem Substance
347827864
ChemSpider
4511170
ChEBI
88667
ChEMBL
CHEMBL1200608
Wikipedia
Octyl_methoxycinnamate
ATC Codes
D02BA02 — Octinoxate
AHFS Codes
  • 84:80.00 — Sunscreen Agents
MSDS
Download (61 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingBasic ScienceHealthy Volunteers1
1CompletedNot AvailableHealthy Volunteers2
1CompletedOtherHealthy Participants1
1CompletedSupportive CareHealthy Volunteers1
1Not Yet RecruitingOtherHealthy Volunteers1
1Not Yet RecruitingTreatmentBladder Small Cell Neuroendocrine Carcinoma / Castration-Resistant Prostate Carcinoma / Metastatic Bladder Urothelial Carcinoma / Metastatic Urethral Urothelial Carcinoma / Prostate Carcinoma Metastatic in the Bone / Prostate Neuroendocrine Neoplasm / Prostate Small Cell Carcinoma / Stage III Bladder Cancer AJCC v8 / Stage III Prostate Cancer AJCC v8 / Stage III Urethral Cancer AJCC v8 / Stage IV Bladder Cancer AJCC v8 / Stage IV Prostate Cancer AJCC v8 / Stage IV Urethral Cancer AJCC v8 / Stage IVA Bladder Cancer AJCC v8 / Stage IVB Bladder Cancer AJCC v8 / Transitional Cell Carcinoma / Ureter Small Cell Carcinoma1
1RecruitingPreventionBreast Cancer Prevention / Mammographic Density1
1, 2CompletedTreatmentObstructive Sleep Apnea (OSA)1
1, 2Not Yet RecruitingTreatmentCancer of the Ovary1
2Active Not RecruitingTreatmentLung Cancers1
2CompletedSupportive CareAdvanced Malignant Neoplasm / Dermatologic Complication / Dermatologic Complications / Neoplasms, Malignant1
2CompletedTreatmentHairy Cell Leukemia (HCL)1
2CompletedTreatmentLeukemias1
2Not Yet RecruitingTreatmentFunctional Popliteal Artery Entrapment Syndrome / Popliteal artery entrapment syndrome1
2RecruitingTreatmentAcute Gouty Arthritis1
2RecruitingTreatmentAcute Promyelocytic Leukemia With PML-RARA / Leukemias1
2RecruitingTreatmentDifferentiated Thyroid Cancer (DTC) / Follicular Thyroid Cancer / Poorly Differentiated Thyroid Gland Carcinoma / Thyroid Cancer, Medullary / Thyroid Cancers / Thyroid Papillary Carcinoma1
2RecruitingTreatmentTriple-Negative Breast Cancer (TNBC)1
2, 3CompletedTreatmentChronic Chronic myelogenous leukemia / Malignant Melanoma / Renal Cell Adenocarcinoma1
3CompletedSupportive CareDermatologic Complications / Unspecified Adult Solid Tumor, Protocol Specific1
3CompletedTreatmentDiabetes Mellitus (DM)1
3CompletedTreatmentMalignant Lymphomas1
3CompletedTreatmentMenstrual Irregularities1
3CompletedTreatmentChronic Chronic myelogenous leukemia1
3Not Yet RecruitingTreatmentAnaesthesia therapy / Shock, Septic1
3Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3Not Yet RecruitingTreatmentMajor Depressive Episode / Suicidal Thoughts1
3RecruitingTreatmentAcute Lymphoblastic Leukemia, Pediatric1
3RecruitingTreatmentAcute Promyelocytic Leukemia With PML-RARA / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Childhood Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Myeloid Neoplasm1
3RecruitingTreatmentCancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Cancer1
3RecruitingTreatmentCervical Cancers1
3RecruitingTreatmentFollicular Lymphoma (FL)1
3TerminatedTreatmentHead and Neck Carcinoma / Lung Cancers / Metastatic Cancers1
4CompletedTreatmentHypermenorrhea1
4CompletedTreatmentMelasma1
4CompletedTreatmentTrigger Finger Disorder1
4Not Yet RecruitingTreatmentEmbryo Transfer1
4Not Yet RecruitingTreatmentHigh Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
4RecruitingTreatmentAcute Kidney Injury (AKI) / Impaired Renal Function / Pharmacokinetics / Renal Failure1
Not AvailableCompletedNot AvailableDexmedetomidine / Endoscopy, Gastrointestinal / Sedation therapy1
Not AvailableCompletedNot AvailableLaryngospasm1
Not AvailableCompletedNot AvailableMidazolam1
Not AvailableCompletedPreventionPigmentation From Visible Light1
Not AvailableCompletedTreatmentFoot Dryness in Patients With NIDDM / Foot Transepidermal Water Loss in Patients in NIDDM1
Not AvailableNot Yet RecruitingTreatmentIntra-nasal Delevery Device / Procedural Sedation1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
StickTopical50 mg
CreamTopical0.9 g/30mL
GelCutaneous
KitTopical
StickTopical7 %
PowderTopical2.0 %
SprayCutaneous
LotionTopical0.975 g/15g
CreamTopical3 g
SalveTopical
LotionTopical4.5 %
LotionTopical30 mg
GelTopical25 mg/1g
OintmentTopical5.5 %
CreamTopical5550 mg/75g
CreamTopical7.5 g/100g
CreamTopical0.6 g/12g
CreamCutaneous
StickTopical7.5 %
LotionTopical3 %
CreamTopical3 %
OintmentTopical
Ointment; stickTopical
Kit
StickTopical3.50 %
EmulsionTopical2.23 %
Cloth; creamTopical
LotionTopical4 %
CreamTopical70 mg/1mL
LiquidTopical6.0 %
LiquidTopical3.00 %
CreamTopical15 mL/200mL
PowderTopical6 %
LotionTopical3.5 %
CreamTopical6 mL/100mL
CreamTopical5.49 g/100g
CreamTopical3 g/50g
CreamTopical6 %
StickOral
EmulsionTopical75 mg/1mL
LipstickTopical5 g/100g
StickTopical306 mg/9g
EmulsionTopical1690 mg/34.48g
CreamTopical1690 mg/34.48g
StickTopical3.4 %
CreamTopical5 %
SolutionTopical
Aerosol, foamTopical
CreamTopical2 mg/1mL
LipstickTopical0.07 g/1g
LipstickTopical
PowderTopical0.05 g/1g
LiquidTopical6 g/100mL
PasteTopical75 mg/1mL
PowderTopical
EmulsionTopical
PowderTopical5.0 %
PowderTopical5 g/100g
EmulsionTopical74.9 mg/1mL
LotionTopical74.9 mg/1mL
EmulsionTopical7.0 %
LiquidTopical2.2 mL/100mL
CreamTopical3.75 mg/50mL
CreamTopical7.5 g/100mL
LiquidTopical7.5 g/100g
CreamTopical7 g/100g
LipstickTopical0.072 g/1g
LiquidTopical5.0 %
EmulsionTopical4 %
PowderTopical0.06 g/1g
LipstickTopical0.068 g/1g
LipstickTopical0.075 g/1g
OintmentTopical6.5 %
LiquidTopical2.2 %
CreamTopical5.6 %
StickTopical6.5 %
CreamTopical0.6 g/15mL
CreamTopical2 g/50mL
CreamTopical7 %
CreamTopical2 g/40mL
LiquidTopical4 g
LotionTopical6.5 %
PowderTopical7.5 g
PowderTopical4 %
PowderTopical7.5 %
EmulsionTopical18.75 mL/250mL
LotionTopical1.1988 mL/30mL
LipstickTopical69 mg/1g
StickTopical68 mg/1g
LipstickTopical68 mg/1g
CreamTopical10 mg/1mL
CreamTopical28 mg/1mL
CreamTopical5 g/100g
PowderTopical50 mg/1g
CreamTopical50 mg/1mL
AerosolTopical50 mg/1mL
LipstickTopical122.5 mg/3.5g
EmulsionTopical30 mg/1mL
EmulsionTopical3 g/100g
Liquid; lotionTopical
LiquidTopical2.20 mL/100mL
StickTopical2 %
LiquidTopical2.23 %
CreamTopical3 mL/75mL
LotionTopical20 mg/1mL
CreamTopical50 mg/1g
LotionTopical67 mg/1mL
CreamTopical2 %
StickCutaneous
CreamTopical3 mL/100mL
LipstickTopical75 mg/1mL
LipstickTopical74 mg/1mL
JellyTopical
CreamTopical2.5 %
SprayTopical3 %
LipstickTopical225 mg/3g
LipstickTopical525 mg/7g
SprayTopical9.75 mL/130mL
LiquidTopical5 %
LiquidTopical2 %
LiquidTopical4 %
CreamTopical2.25 mL/30mL
CreamTopical4 %
LotionTopical2.0 %
CreamTopical1.5 g/30g
CreamTopical1.5 mL/30mL
LotionTopical2275 mg/35mL
SoapTopical
CreamTopical3.75 mL/50mL
LotionTopical50 mg/1mL
PowderTopical0.975 g/13g
LiquidTopical0.72 mL/24mL
LotionTopical0.9 mL/30mL
LiquidTopical0.9 mL/30mL
PowderTopical0.75 g/10g
StickTopical0.12 g/4g
LotionTopical1.95 g/30mL
CreamTopical35 mg/1mL
CreamTopical3.5 g/100g
LotionTopical35 mg/1mL
LotionTopical3.5 g/100mL
LotionTopical2.1 g/30mL
LiquidTopical0.07 g/1mL
LiquidTopical0.045 g/1g
CreamTopical1.35 g/30g
Lotion / shampooTopical
OintmentTopical1.0 %
CreamTopical7.5 g
CreamTopical6 mL/30mL
CreamTopical1.8 g/30mL
LiquidTopical30 mg/1mL
LiquidTopical70 mg/1mL
CreamTopical49 mg/1g
LotionTopical75 mg/1mL
LiquidTopical60 mg/1mL
CreamTopical60 mg/1mL
CreamTopical60 mg/100mL
EmulsionTopical5.0 %
LiquidTopical3.5 %
LiquidTopical7 %
LiquidTopical7 mL/100mL
LiquidTopical7.5 %
GelTopical
CreamTopical0.525 g/7mL
LotionTopical7.5 %
LotionTopical
CreamTopical7.5 %
CreamTopical
LotionTopical3 g/30g
LotionTopical30 mg/1mL
LiquidTopical2.1 mL/30mL
LotionTopical70 mg/1mL
LiquidTopical1.5 mL/20mL
LotionTopical45 mg/1mL
PowderTopical40 mg/1g
OintmentTopical5 %
PowderTopical0.42 g/14g
CreamTopical10 g/100g
LiquidTopical7.5 mL/100mL
LipstickTopical2.2 mL/100mL
LiquidTopical3 %
SuspensionTopical
StickTopical10 mg/1g
StickTopical30 mg/1g
LotionTopical2 g/100mL
CreamTopical7.5 g/30g
EmulsionTopical2.25 g/30g
EmulsionTopical1.5 g/30g
Kit; lotionTopical
CreamTopical1.5 g/100g
LotionTopical0.05 g/1mL
LotionTopical7 %
AerosolTopical
CreamTopical3.5 g/50mL
OilTopical16.8 mg/1mL
OilTopical19.3 mg/1mL
SprayTopical19.8 mg/1mL
OilTopical2 g/100g
LotionCutaneous
CreamTopical11.25 mL/150mL
LotionTopical5.0 %
CreamTopical3.75 g/50mL
LotionTopical6 %
OilTopical
StickTopical4.9 %
LiquidTopical50 mg/1mL
LipstickTopical3.5 g/100g
Cream; kitTopical
PowderCutaneous
CreamTopical7.5 mL/100mL
StickTopical5 %
PowderTopical2 %
CreamTopical1.3 g/30mL
PasteTopical7.5 g/100g
LipstickTopical7.5 g/100g
LipstickTopical0.28 g/4g
CreamTopical7.0 %
LotionTopical2.25 g/30mL
SuspensionTopical7.5 %
GelTopical3 g/100mL
CreamTopical4 g/100mL
SuspensionTopical4 %
LipstickTopical20 mg/1mL
CreamTopical6.0 %
EmulsionTopical7.5 %
LotionTopical7.4 %
CreamTopical7.4 %
CreamTopical2036 mg/30mL
CreamTopical1832 mg/30mL
StickTopical196 mg/4g
PasteTopical
EmulsionTopical4.5 %
LipstickTopical196 mg/4g
StickTopical4.996 %
StickTopical4 %
LotionTopical1.125 mL/15mL
LotionTopical2.25 mL/30mL
LiquidTopical6 %
LotionTopical60 mg/1mL
StickTopical7.0 %
LipstickTopical75 mg/1g
CreamTopical4.5 %
SprayTopical16.7 mg/1mL
LiquidTopical
Spray, suspensionTopical
LotionTopical2 %
StickTopical
SprayOral
EmulsionTopical2 %
LiquidTopical2.5 %
GelTopical3.5 mL/100mL
PasteTopical67.4 mg/1g
LiquidTopical1.95 g/30mL
SpongeTopical
SprayTopical
StickTopical3.5 %
LotionTopical2.5 %
LotionTopical5.5 %
Liquid; sprayTopical
LiquidTopical1 %
GelTopical0.075 g/1g
StickTopical3 %
Lotion; sprayTopical
LotionTopical6 g/100mL
EmulsionTopical3 %
EmulsionTopical5 %
CreamTopical3.0 %
LotionTopical7.50 %
CreamTopical30 mg/1mL
CreamTopical75 mg/1mL
LiquidTopical25 mg/1mL
PowderTopical25 mg/1mL
CreamTopical3 g/100mL
Cream, augmentedTopical
CreamTopical0.36 g/7.2g
PowderTopical5 %
PowderTopical5.2 %
CreamTopical68 mg/1mL
CreamTopical2.0 mL/100mL
LipstickTopical7.0 g/100g
CreamTopical6.3 g/100g
LotionTopical5 g/100g
LotionTopical7 g/100g
LiquidTopical5 g
LipstickTopical210 mg/3g
LipstickTopical0.225 g/3g
LotionTopical4.995 %
CreamTopical4.995 %
Aerosol, sprayTopical
ClothTopical
LiquidTopical0.075 mL/1mL
LiquidTopical0.075 g/1mL
LotionTopical1.25 %
Cream; liquidTopical
LiquidTopical5.4 mL/100mL
LotionTopical6.0 %
CreamTopical4.0 %
LotionTopical5 %
EmulsionTopical50 mg/1mL
SprayTopical3 g/100g
LiquidTopical40 mg/1mL
LipstickTopical40 mg/1g
LotionTopical3 g/100g
LotionTopical65 mg/1mL
LotionTopical2.1 mL/30mL
LipstickTopical0.076 g/3.8g
PowderTopical0.6 g/10g
CreamTopical74.9 mg/1mL
LotionTopical68 mg/1mL
LotionTopical40 mg/1mL
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)-25°CMSDS
boiling point (°C)185-195°C at 1mbarMSDS
water solubility<0.1 g/100 mL at 27°CA19210
logP5.8MSDS
Predicted Properties
PropertyValueSource
Water Solubility0.000452 mg/mLALOGPS
logP5.62ALOGPS
logP5.38ChemAxon
logS-5.8ALOGPS
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area35.53 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity86.44 m3·mol-1ChemAxon
Polarizability34.84 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as cinnamic acid esters. These are compound containing an ester derivative of cinnamic acid.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Cinnamic acids and derivatives
Sub Class
Cinnamic acid esters
Direct Parent
Cinnamic acid esters
Alternative Parents
Styrenes / Phenoxy compounds / Methoxybenzenes / Anisoles / Fatty acid esters / Alkyl aryl ethers / Enoate esters / Monocarboxylic acids and derivatives / Organic oxides / Hydrocarbon derivatives
show 1 more
Substituents
Cinnamic acid ester / Phenoxy compound / Anisole / Methoxybenzene / Phenol ether / Styrene / Alkyl aryl ether / Fatty acid ester / Monocyclic benzene moiety / Fatty acyl
show 13 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on November 30, 2015 12:10 / Updated on November 20, 2018 13:19